Evidence map›Paper›PMID 32601815›Full record

ArticleJournal of cancer research and clinical oncology2020

Head and body/tail pancreatic neuroendocrine tumors have different biological characteristics and clinical outcomes.

Wentong Mei, Yixuan Ding, Shuo Wang, Yuchen Jia, Feng Cao, Fei Li

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Wentong MeiDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing, China.
Yixuan DingDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing, China.
Shuo WangDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing, China.
Yuchen JiaDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing, China.
Feng CaoDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing, China. caofeng1221@163.com.
Fei LiDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing, China. feili36@ccmu.edu.cn.ORCID http://orcid.org/0000-0002-0532-9054
Capital Medical University · CN

Funding

Beijing Municipal Science & Technology Commission Z171100001017077
6 · The paper itself

Abstract

purposeThe incidence of pancreatic neuroendocrine tumors (pNETs) has continued to increase, but for pNETs, there is still no distinction between treatments based on anatomical location. We aim to determine whether NETs located at the head and body/tail of the pancreas are different. PATIENTS AND

methodsWithin the Surveillance, Epidemiology, and End Results database (2004-2016), we focused on pNETs patients with comprehensive information. The patients were divided into two groups based on tumors' location. We compared the characteristics of the two groups and assessed the risk factors for lymphatic metastasis. Survival analysis was performed based on the biological characteristics of the tumor.

resultsIn all 3011 patients, pNETs were more common in the body/tail (62.94%) than in the head (37.06%) of the pancreas. The risk factors for lymph node metastasis in the two groups were different. Nonmetastatic, low-grade pancreatic body/tail NETs had the best prognosis (p < 0.001). For low-grade tumors (G1-G2), lymphatic metastasis did not significantly affect the prognosis of patients with pancreatic head NETs (p = 0.098) but affected the overall survival of patients with pancreatic body/tail NETs (p < 0.001). The tumors at the pancreatic head were larger (p = 0.001), more likely to have positive lymph nodes (p < 0.001) and more prone to locally advanced and distant invasion (p < 0.001). The prognosis of pancreatic head NETs 21-40 mm was worse than that of body/tail pNETs (p < 0.001). For non-functional NETs, the overall survival of pancreatic body/tail tumors was better (p < 0.001).

conclusionThe pancreatic head and pancreatic body/tail NETs have different biological characteristics and clinical outcomes and they should be treated differently.

Indexed as

AgedFemaleHumansLymphatic MetastasisMaleMiddle AgedNeuroendocrine TumorsPancreatic NeoplasmsRetrospective StudiesRisk FactorsSEER ProgramSurvival AnalysisClinical outcomesPancreatic neuroendocrine tumorsPrognosisTumor biological characteristics

Identifiers

PMID32601815
PMCPMC11804438
OpenAlexW3038131020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.